Published in Maedica (Buchar) on December 01, 2010
Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. Lancet (2003) 19.90
Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med (2002) 12.95
The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. N Engl J Med (2001) 5.50
B-type natriuretic peptide in cardiovascular disease. Lancet (2003) 4.80
N-terminal pro-B-type natriuretic peptide and long-term mortality in acute coronary syndromes. Circulation (2002) 3.79
Localization and mechanism of secretion of B-type natriuretic peptide in comparison with those of A-type natriuretic peptide in normal subjects and patients with heart failure. Circulation (1994) 3.63
Utility of B-type natriuretic peptide in the diagnosis of congestive heart failure in an urgent-care setting. J Am Coll Cardiol (2001) 2.26
Different secretion patterns of atrial natriuretic peptide and brain natriuretic peptide in patients with congestive heart failure. Circulation (1993) 2.04
Evaluation of B-type natriuretic peptide for risk assessment in unstable angina/non-ST-elevation myocardial infarction: B-type natriuretic peptide and prognosis in TACTICS-TIMI 18. J Am Coll Cardiol (2003) 1.89
B-type natriuretic peptide at presentation and prognosis in patients with ST-segment elevation myocardial infarction: an ENTIRE-TIMI-23 substudy. J Am Coll Cardiol (2004) 1.75
A fresh look at reperfusion injury. Cardiovasc Res (1998) 1.63
Brain natriuretic peptide increases acutely and much more prominently than atrial natriuretic peptide during coronary angioplasty. Clin Cardiol (2000) 1.61
N-terminal pro brain natriuretic peptide on admission for early risk stratification of patients with chest pain and no ST-segment elevation. J Am Coll Cardiol (2002) 1.59
Gene expression of brain natriuretic peptide in isolated atrial and ventricular human myocardium: influence of angiotensin II and diastolic fiber length. Circulation (2000) 1.31
B-type natriuretic peptide levels: diagnostic and prognostic in congestive heart failure: what's next? Circulation (2002) 1.28
Prognostic value of N-terminal pro-atrial and pro-brain natriuretic peptide in patients with acute coronary syndromes. Am J Cardiol (2002) 1.25
Plasma cardiac natriuretic peptide determination as a screening test for the detection of patients with mild left ventricular impairment. Heart (1996) 1.21
Transient increase in plasma brain (B-type) natriuretic peptide after percutaneous transluminal coronary angioplasty. Clin Cardiol (2000) 1.12
Plasma level of B-type natriuretic peptide as a prognostic marker after acute myocardial infarction: a long-term follow-up analysis. Circulation (2004) 1.09
N-terminal pro-brain natriuretic peptide on admission has prognostic value across the whole spectrum of acute coronary syndromes. Circulation (2004) 1.08
Natriuretic peptides: physiology, therapeutic potential, and risk stratification in ischemic heart disease. Am Heart J (1998) 1.06
Prognostic value of N-terminal proatrial natriuretic factor plasma levels measured within the first 12 hours after myocardial infarction. Thrombolysis in Myocardial Infarction (TIMI) II Investigators. J Am Coll Cardiol (1995) 0.83
Visit-to-Visit Blood Pressure Variability and Arterial Stiffness Independently Predict Cardiovascular Risk Category in a General Population: Results from the SEPHAR II Study. Hellenic J Cardiol (2015) 0.76
Perspectives on hypertension's prevalence, treatment and control in a high cardiovascular risk East European country: data from the SEPHAR III survey. J Hypertens (2017) 0.75